Longitudinal study of humoral and cellular responses to COVID-19 mRNA vaccines with and without 3rd ("booster") dose in MS patients on ocrelizumab: 24-week results from VIOLA (NCT04843774)
MULTIPLE SCLEROSIS JOURNAL(2022)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要